Molecular-Targeted Therapies in Head and Neck Cancer

Shyam Rao, Matthew G. Fury, David G. Pfister

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The increasing understanding of tumor biology has opened the door to a new class of biological agents directed at specific molecular targets in the treatment of squamous cell carcinomas of the head and neck. These targeted agents present the opportunity to more effectively attack the crucial cellular pathways contributing to tumor growth and survival, while minimizing toxicity. Cetuximab, which targets epidermal growth factor (EGF) receptor signaling, was the first such biological agent to be proven effective in head and neck squamous cell cancers. Currently, there are dozens of targeted agents at various stages of testing for use in the treatment of head and neck cancers. In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalSeminars in Radiation Oncology
Volume22
Issue number3
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Molecular Targeted Therapy
Biological Factors
Head and Neck Neoplasms
Epidermal Growth Factor Receptor
Squamous Cell Neoplasms
Sirolimus
Phosphatidylinositol 3-Kinases
Vascular Endothelial Growth Factor A
Neoplasms
Head
Therapeutics
Growth
Cetuximab
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Molecular-Targeted Therapies in Head and Neck Cancer. / Rao, Shyam; Fury, Matthew G.; Pfister, David G.

In: Seminars in Radiation Oncology, Vol. 22, No. 3, 01.07.2012, p. 207-213.

Research output: Contribution to journalReview article

Rao, Shyam ; Fury, Matthew G. ; Pfister, David G. / Molecular-Targeted Therapies in Head and Neck Cancer. In: Seminars in Radiation Oncology. 2012 ; Vol. 22, No. 3. pp. 207-213.
@article{095520d0ba324c6796075273a8da7581,
title = "Molecular-Targeted Therapies in Head and Neck Cancer",
abstract = "The increasing understanding of tumor biology has opened the door to a new class of biological agents directed at specific molecular targets in the treatment of squamous cell carcinomas of the head and neck. These targeted agents present the opportunity to more effectively attack the crucial cellular pathways contributing to tumor growth and survival, while minimizing toxicity. Cetuximab, which targets epidermal growth factor (EGF) receptor signaling, was the first such biological agent to be proven effective in head and neck squamous cell cancers. Currently, there are dozens of targeted agents at various stages of testing for use in the treatment of head and neck cancers. In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation.",
author = "Shyam Rao and Fury, {Matthew G.} and Pfister, {David G.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.semradonc.2012.03.005",
language = "English (US)",
volume = "22",
pages = "207--213",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Molecular-Targeted Therapies in Head and Neck Cancer

AU - Rao, Shyam

AU - Fury, Matthew G.

AU - Pfister, David G.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - The increasing understanding of tumor biology has opened the door to a new class of biological agents directed at specific molecular targets in the treatment of squamous cell carcinomas of the head and neck. These targeted agents present the opportunity to more effectively attack the crucial cellular pathways contributing to tumor growth and survival, while minimizing toxicity. Cetuximab, which targets epidermal growth factor (EGF) receptor signaling, was the first such biological agent to be proven effective in head and neck squamous cell cancers. Currently, there are dozens of targeted agents at various stages of testing for use in the treatment of head and neck cancers. In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation.

AB - The increasing understanding of tumor biology has opened the door to a new class of biological agents directed at specific molecular targets in the treatment of squamous cell carcinomas of the head and neck. These targeted agents present the opportunity to more effectively attack the crucial cellular pathways contributing to tumor growth and survival, while minimizing toxicity. Cetuximab, which targets epidermal growth factor (EGF) receptor signaling, was the first such biological agent to be proven effective in head and neck squamous cell cancers. Currently, there are dozens of targeted agents at various stages of testing for use in the treatment of head and neck cancers. In this article, we review strategies aimed at key pathways, including EGF receptor signaling, the Vascular Endothelial Growth Factor (VEGF) pathway, and PI3K/AKT/mammalian target of rapamycin activation.

UR - http://www.scopus.com/inward/record.url?scp=84862126545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862126545&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2012.03.005

DO - 10.1016/j.semradonc.2012.03.005

M3 - Review article

C2 - 22687945

AN - SCOPUS:84862126545

VL - 22

SP - 207

EP - 213

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 3

ER -